Kazia Therapeutics (KZIA) Operating Expenses (2009 - 2016)

Kazia Therapeutics (KZIA) posted Operating Expenses of -$6.6 million for Q4 2016, down 47004.62% on a QoQ basis from $14154.7 in Q4 2011.

Kazia Therapeutics (KZIA) Operating Expenses (2009 - 2016) Analysis & Trends

Kazia Therapeutics' Operating Expenses history runs 4 years deep, the most recent figure standing at -$6.6 million for Q4 2016.

Quarterly Operating Expenses changed N/A year-over-year to -$6.6 million in Q4 2016, while the trailing twelve-month figure through Jun 2018 was -$6.6 million (changed 0.0% YoY) and the FY2025 annual result came in at $10.3 million, down 49.61% from the prior year.
Operating Expenses was -$6.6 million for Q4 2016 at Kazia Therapeutics, down from $14154.7 in the prior quarter.
Across five years, Operating Expenses topped out at -$6.6 million in Q4 2016 and bottomed at -$6.6 million in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Opex (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-28.01 Mn
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	15.76 Mn
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	1.10 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	1.85 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	2.96 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-	32.68 Mn
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-919.00 Mn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	445.22 Mn
10	Kazia Therapeutics	19.25 Bn	19.25 Bn	-	-

Download Data